ArticleApplied and environmental microbiology2016
The Redox Cofactor F
Article in Applied and environmental microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Flavin and deazaflavin biosynthesis in mycobacteria: relevance to physiology, implications for drug discovery, MR-1 antigenicity, and vaccine development.Frontiers in immunology · 2025Review
- Novel Prodrug Strategies for the Treatment of Tuberculosis.Chemistry, an Asian journal · 2024Review
- Widespread loss-of-function mutations implicating preexisting resistance to new or repurposed anti-tuberculosis drugs.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024Article
- Cofactor FHeliyon · 2024Article
- Glucose-6-phosphate dehydrogenase and its 3D structures from crystallography and electron cryo-microscopy.Acta crystallographica. Section F, Structural biology communications · 2024Review
- The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis.Nature communications · 2023Article
- Mycobacterium smegmatis: The Vanguard of Mycobacterial Research.Journal of bacteriology · 2023Review
- Cofactor F420: an expanded view of its distribution, biosynthesis and roles in bacteria and archaea.FEMS microbiology reviews · 2021Article
- Potency boost of aProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Mutations inAntimicrobial agents and chemotherapy · 2020Article
- Redox Coenzyme FApplied and environmental microbiology · 2020Article
- Article
- Untargetted Metabolomic Exploration of theBiomolecules · 2020Article
- Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.PLoS pathogens · 2020Article
- A revised biosynthetic pathway for the cofactor FNature communications · 2019Article
- Reconstructing the evolutionary history of FScientific reports · 2018Article
- Mechanistic insights into FBiochimica et biophysica acta. Proteins and proteomics · 2018Article
- Discovery and characterization of an FApplied microbiology and biotechnology · 2017Article
- Cofactor Tail Length Modulates Catalysis of Bacterial FFrontiers in microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A defining feature of mycobacterial redox metabolism is the use of an unusual deazaflavin cofactor, F
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.